文献速递脑血管病

按风险分层比较替格瑞洛联合阿司匹林与氯吡格雷联合阿司匹林在CYP2C19功能缺失携带者轻型卒中或短暂性脑缺血发作中的疗效

Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers With Minor Stroke or TIA Stratified by Risk Profile.
PubMed 文献 · Neurology · 2022-12-19

该研究基于CHANCE-2试验数据,纳入6,412例CYP2C19功能缺失携带者,按Essen卒中风险评分(ESRS)分层(<3为低风险,≥3为高风险),比较替格瑞洛联合阿司匹林与氯吡格雷联合阿司匹林的疗效与安全性。结果显示,在低风险患者中替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林降低90天随访新发卒中风险(HR 0.65;95%CI 0.48-0.82),高风险患者中未见获益(HR 0.97;95%CI 0.73-1.29),交互作用P=0.02;严重或中度出血风险分层间无差异(交互作用P=0.24),但低风险患者中替格瑞洛联合阿司匹林的总出血发生率高于氯吡格雷联合阿司匹林(交互作用P<0.01)。

要点

  • 低风险(ESRS<3)CYP2C19功能缺失携带者中,替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林降低90天新发卒中风险(HR 0.65)。
  • 高风险(ESRS≥3)患者中两种治疗无显著差异(HR 0.97;95%CI 0.73-1.29),交互作用P=0.02。
  • 低风险患者中替格瑞洛联合阿司匹林的总出血发生率高于氯吡格雷联合阿司匹林(交互作用P<0.01),严重或中度出血无差异(交互作用P=0.24)。

核心结论

  • CHANCE-2试验的事后分析显示,低复发风险(ESRS<3)的CYP2C19功能缺失携带者轻型卒中或TIA患者从替格瑞洛联合阿司匹林治疗中获益大于氯吡格雷联合阿司匹林,而高风险(ESRS≥3)患者未见此获益。

研究设计与样本

  • 基于CHANCE-2试验数据的事后分析,共纳入6,412例CYP2C19功能缺失携带者,按Essen卒中风险评分(ESRS)分层:<3为低风险,≥3为高风险。

主要发现

  • 低风险患者中,替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林降低主要结局(90天随访新发卒中)风险(HR 0.65;95%CI 0.48-0.82)。
  • 高风险患者中,替格瑞洛联合阿司匹林与氯吡格雷联合阿司匹林的主要结局风险无显著差异(HR 0.97;95%CI 0.73-1.29),交互作用P=0.02。
  • 次要结局总体与主要结局方向一致。
  • 主要安全结局严重或中度出血在风险分层间无差异(交互作用P=0.24)。
  • 低风险患者中,替格瑞洛联合阿司匹林的总出血发生率高于氯吡格雷联合阿司匹林(交互作用P<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Genotype data of the Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) trial showed that efficacy of clopidogrel aspirin depended on CYP2C19 genotype and risk profile. A stratification of patients who carried CYP2C19 loss-of-function (LOF) alleles according to the risk of recurrent stroke may be important for selecting optimal antiplatelet therapy. We aimed to compare the efficacy and safety of ticagrelor aspirin with clopidogrel aspirin in CYP2C19 LOF carriers with minor stroke or transient ischemic attack (TIA) stratified by risk profile. METHODS: Data were obtained from Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial. Low-risk and high-risk profiles were defined by Essen Stroke Risk Score (ESRS) (<3 [low risk] and ≥3 [high risk], respectively). RESULTS: A total of 6,412 CYP2C19 LOF carriers were enrolled; ticagrelor aspirin was associated with a reduced risk of primary outcome (new stroke within 90-day follow-up) in patients at low risk (hazard ratio [HR], 0.65; 95% CI, 0.48-0.82), but not in those at high risk (HR, 0.97; 95% CI, 0.73-1.29), compared with clopidogrel aspirin (p = 0.02 for interaction). Secondary outcomes generally went in the same direction as the primary outcome. The primary safety outcome of severe or moderate bleeding did not differ based on risk profile (p = 0.24 for interaction), although the incidence of total bleeding was greater with ticagrelor aspirin than with clopidogrel aspirin among patients at low risk (p < 0.01 for interaction). Analysis in the per-protocol population yielded similar results. DISCUSSION: This post hoc analysis of CHANCE-2 trial showed that CYP2C19 LOF carriers with minor stroke or TIA at low risk of recurrent stroke received a greater benefit from ticagrelor aspirin than from clopidogrel aspirin. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that CYP2C19 LOF carriers with minor stroke or TIA at low risk, but not at high risk, of recurrent stroke (by the ESRS) received a greater benefit from ticagrelor aspirin than from clopidogrel aspirin. TRIAL REGISTRATION INFORMATION: URL: www. CLINICALTRIALS: gov. Unique identifier: NCT04078737.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wang A, Meng X, Tian X, et al. Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers With Minor Stroke or TIA Stratified by Risk Profile. Neurology. 2022. PMID: 36535779. doi:10.1212/WNL.0000000000201454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。